Ilomastat
chemical compound
Ilomastat (INN; development code GM6001; proprietary name Galardin) is a broad-spectrum matrix metalloproteinase inhibitor.
This chemotherapy agent is considered to have application in skincare products for its antiaging properties.
Ilomastat is a member of the hydroxamic acid class of reversible metallopeptidase inhibitors. The anionic state of the hydroxamic acid group forms a bidentate complex with the active site zinc.
Examples of enzymes that ilomastat inhibit include rabbit MMP9, thermolysin, peptide deformylase, and anthrax lethal factor endopeptidase (LF) produced by the bacterium Bacillus anthracis.
Begin with the source’s own compact description: “Ilomastat” is chemical compound. The dossier treats that line as a proposition to test through Ilomastat, chemical and compound, not as a finished interpretation.
Why this record matters
The phrase “chemical compound” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Dec 30, 2025. The linked authority identifier is Q5513695. None of the 0 selected statements returned an explicit reference.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Ilomastat”, its source revision and the description used here.
- Expand the search: follow Ilomastat primary sources, Ilomastat archive and Ilomastat research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Ilomastat”?
- Which observation, specimen, dataset or publication supports the account?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “Ilomastat” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.